EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias
Dates: April 25-26, 2025
Location: Berlin, Germany
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia
Overview
The EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML) will focus on:
- Therapy-related AML
- AML evolving from a previous myeloid disease (such as MDS or MFS/MPN)
Special attention will be given to:
- Clonal hematopoiesis and clonal evolution mechanisms that play a significant role in disease ontogenesis
- Special clinical situations
- Treatment
Program
The meeting will cover intrinsic and extrinsic pathogenetic mechanisms, including:
- Susceptibility factors to sAML (such as germ-line and acquired molecular lesions)
- The role of the bone marrow microenvironment
It will also cover clinically important aspects and special situations, such as:
- sAML following childhood malignancies
- Leukemogenic effects of drugs
- Prevention/surveillance strategies
- sAML following gene therapy
- CAR-T cell therapy for sAML
- AML of donor origin in the context of allogeneic stem cell transplantation
- Current treatment options for sAML
Major experts in the molecular characterization of sAML and the translational consequences in disease diagnosis, management, and treatment will join the meeting and be part of an intensive scientific exchange.
Learning objectives
After attending this meeting, participants will be able to:
- Classify sAML and apply current prognostic stratification tools
- Identify patient with germ-line and acquired predisposition to sAML and other risk factor for sAML development
- Design prevention and surveillance programs
- Understand the mechanisms of clonal progression from other myeloid diseases and sAML development as a result of cancer treatment
- Explain the role of bone marrow microenvironment
- Discuss innovative treatment approaches
With this meeting, we would particularly encourage young researchers and clinician scientists to present their data on sAML in one of the abstract or poster sessions.
Target audience
The meeting is intended for:
- Hematologist-oncologists
- Non-malignant hematologists
- Pediatricians
- Transplant specialists
- Clinical laboratory specialists
- Research scientists
- Patient advocates
EHA Curriculum sections covered
Primary
- Myeloid malignancies: Acute myeloid leukemia (secondary AML).
Secondary
- Non-malignant disorders: BM failure.
- Myeloid malignancies: Myeloproliferative neoplasms, MDS/MPN, MDS.
- Laboratory diagnosis: Molecular genetics.
- General skills: Cellular and molecular biology of hematopoietic cells.
Registration
Registration is now open. For details, visit the registration & accommodation page.
Abstract & clinical case submission
Abstract & clinical case submission is an important part of this meeting. The submission is now open and please visit the abstract & clinical case submission page for more details.
Venue
Mercure Hotel MOA Berlin
Stephanstrasse 41
10559 Berlin
Germany
EBAH
Continuing Medical Education (CME) is widely accepted to encourage individual practitioners to maintain and develop professional knowledge and skills keeping up-to-date with latest developments within the field. The meeting will be accredited by the EBAH system. Participants of this meeting are eligible to receive one Continuing Medical Education (CME) credit point for every hour of accredited activity from the EBAH system.
More on this topic from EHA
EHA members can access an EHA Campus course on MDS, MPN, and AML: Unraveling Commonalities and Innovations. This resource features adapted content from the previous EHA meeting on this topic.
If you're not yet an EHA member, you can find out about the benefits of joining our vibrant global community by visiting our membership pages.
Back